Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
IQV Price Action
Last 7 days
2.1%
Last 30 days
-12.0%
Last 90 days
-23.8%
Trailing 12 Months
-30.9%
IQV RSI Chart
IQV Valuation
IQV Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
IQV Fundamentals
IQV Revenue
IQV Earnings
IQV Profitability
IQV Investor Care
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Research And Development Solutions
| |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2024 | 15.1B | 15.2B | 15.3B | 15.4B |
| 2023 | 14.5B | 14.7B | 14.9B | 15.0B |
| 2022 | 14.0B | 14.1B | 14.3B | 14.4B |
| 2021 | 12.0B | 12.9B | 13.5B | 13.9B |
| 2020 | 11.2B | 10.9B | 11.0B | 11.4B |
| 2019 | 10.5B | 10.7B | 10.9B | 11.1B |
| 2018 | 9.9B | 10.1B | 10.2B | 10.4B |
| 2017 | 7.7B | 8.5B | 9.5B | 9.7B |
| 2016 | 5.9B | 6.0B | 6.1B | 6.8B |
| 2015 | 5.5B | 5.6B | 5.6B | 5.7B |
| 2014 | 5.2B | 5.2B | 5.4B | 5.5B |
| 2013 | 4.9B | 5.0B | 5.0B | 5.1B |
| 2012 | 4.5B | 4.6B | 4.7B | 4.9B |
| 2011 | 0 | 0 | 0 | 4.3B |
Get all data in R, Python etc through our Historical Stock Data APIs
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.
| CEO | Mr. Ari Bousbib |
|---|---|
| WEBSITE | iqvia.com |
| SECTOR | Healthcare |
| INDUSTRY | Diagnostics & Research |
| EMPLOYEES | 65535 |
